Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible-or Not Too Late to Start?
- Design
- Narrative review · None outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: the review is about adults with type 2 diabetes and CKD G4-G5, conditions the target population does not have; no age or BMI data are given.
- Could weight loss explain it?
- Not applicableNot applicable: a narrative review with no GLP-1 outcome result to assess.
- Study tier
- Not ratedNOT_RATED: narrative review of post hoc and subgroup analyses, meta-analyses, pooled analyses and observational data, with no new primary data.
- Assessment
- Version 2 · Two independent AI reviews agreed · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This narrative review looks at four drug groups, including GLP-1 receptor agonists, for adults with type 2 diabetes and advanced chronic kidney disease (stages G4-G5). Drawing on post hoc and subgroup analyses of earlier trials, meta-analyses and observational data, it concludes that a monitoring-based approach is generally supported in G4, while decisions in G5 are more individual and extrapolated. It reports no new data and gives no effect estimate for GLP-1 drugs.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists
- Dose
- various
- Comparator
- not reported in abstract
- Primary outcome
- what the evidence supports for initiating, continuing, withholding, discontinuing and reinitiating each of the four pillars, including GLP-1 receptor agonists, in type 2 diabetes with CKD G4-G5
- Effect
- not reported in abstract
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- not reported in abstract
- Limitations
- Narrative rather than systematic review; the landmark trials largely enrolled people down to eGFR ∼20-30 mL/min/1.73 m2, so advice for CKD G4-G5 rests on post hoc, subgroup, pooled and observational data, and the authors call decisions in G5 explicitly extrapolative.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- type 2 diabetes required (review scope)
- Cvd status
- not reported in abstract
- Ckd status
- CKD G4-G5 required (review scope)
- Baseline condition
- type 2 diabetes with CKD G4-G5
- Inclusion exclusion
- adults with type 2 diabetes and CKD G4-G5 (review scope)
Study quality details
- Study design
- Narrative review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- n/a
- Comparator
- not reported in abstract
- Follow up duration
- not stated
- Outcome type
- none
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no CI reported
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
The 4-pillar therapy-renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, the nonsteroidal mineralocorticoid receptor antagonist finerenone, and glucagon-like peptide 1 receptor agonists-is increasingly applied to improve kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease (CKD). However, landmark trials underpinning current recommendations largely enrolled participants down to estimated glomerular filtration rate thresholds of ∼20-30 mL/min/1.73 m2, leaving uncertainty in CKD G4-G5. This uncertainty contributes to an implementation gap in advanced CKD, which is as follows: missing pillars are often not initiated, therapies are interrupted during clinical complications, and they are not reinitiated once acute triggers resolve despite high absolute kidney and cardiovascular risk. This narrative review summarizes what current evidence does-and does not-support for initiating, continuing, temporarily withholding, discontinuing, and reinitiating each pillar in type 2 diabetes and CKD G4-G5. We integrate posthoc and subgroup analyses of landmark trials, meta-analyses, and pooled analyses, including low-estimated glomerular filtration rate strata and observational real-world data. The main practical message is that current evidence generally supports a monitoring-based approach to 4-pillar therapy in CKD G4, whereas decisions in CKD G5 remain more individualized and explicitly extrapolative. For clinicians, the key priority is to identify missing pillars, avoid unnecessary permanent discontinuation, and use structured reinitiation when clinically appropriate.